Imatinib, dasatinib and nilotinib: a review of adverse cutaneous reactions with emphasis on our clinical experience. - Wikidata - awgldk - TriplyDB

Imatinib, dasatinib and nilotinib: a review of adverse cutaneous reactions with emphasis on our clinical experience.

Imatinib, dasatinib and nilotinib: a review of adverse cutaneous reactions with emphasis on our clinical experience.

http://www.wikidata.org/entity/Q38101103

about

European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia Vinculin phosphorylation differentially regulates mechanotransduction at cell-cell and cell-matrix adhesions Drug-induced photoallergic and phototoxic reactions - an update.Tyrosine kinase inhibitors as reversal agents for ABC transporter mediated drug resistance.Erythema nodosum-like lesions during BRAF inhibitor therapy: Report on 16 new cases and review of the literature.Management of adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukemia.C-kit mutations determine dasatinib mechanism of action in HMC-1 neoplastic mast cells: dasatinib differently regulates PKCδ translocation in HMC-1(560) and HMC-1(560,816) cell lines.A newborn with teratogenic effect of imatinib mesylate: a very rare case report Long-term mucocutaneous adverse effects of imatinib in Indian chronic myeloid leukemia patients.Nilotinib-induced panniculitis in a patient with chronic myelogenous leukaemia.Ponatinib-induced widespread ichthyosiform eruption.Multiple squamous cell carcinomas following introduction of nilotinib.Imatinib mesylate-induced pseudoporphyria in two children.Xanthelasma palpebrarum: a new side effect of nilotinib.

P2860

Q26749324-B2B8D0ED-DCC1-441F-A133-C7A0320A28E0 Q30577227-CA95EFBE-7D36-4EA7-A465-A452DBB28D5C Q38189112-3B7EA701-05B9-4A71-99CD-C938F1AB3251 Q38246305-E93547EF-8ADD-4F7A-9F3F-F3325DE75785 Q38370667-6EEB3D7E-2F39-481A-AA8A-359C7C59BABB Q38392679-B25F721F-646F-44D9-8491-E52A62C1F5DD Q38852257-F248F966-30F9-454F-B89B-6D57E5B4E4F1 Q42756487-914043FC-1317-4E95-8029-AB45FA576072 Q47561716-6AD658B2-5EF2-495F-ABA8-CCAF3E2BFAC4 Q50213000-D22A6489-D082-4D17-80AB-12D828D89EE7 Q53709484-7807F854-8B07-4FE3-9314-7C0EA04D60C6 Q54327179-B4D1B7B8-B115-4E0F-B6F5-223D7BD99029 Q54345379-B1346B00-4C80-4F6D-AACE-F456A0C2D5FD Q55032171-E2EE85CF-46BF-4642-9BC5-1368C3788507

P2860

Imatinib, dasatinib and nilotinib: a review of adverse cutaneous reactions with emphasis on our clinical experience.

http://www.wikidata.org/entity/Q38101103

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Imatinib, dasatinib and niloti ...... is on our clinical experience.

@en

type

label

Imatinib, dasatinib and niloti ...... is on our clinical experience.

@en

prefLabel

Imatinib, dasatinib and niloti ...... is on our clinical experience.

@en

P1433

Q38101103-3E1D0DC7-22E9-4A44-80E7-4994AF69F725

P1476

Q38101103-627FBF59-F8B3-491D-A121-F9BFBA7E265A

P2093

Q38101103-C494DCE9-7CF2-49BB-BED6-3BC3F48235BE

P2860

Q38101103-00755F4D-1E3D-45FB-A351-3CF662367A74

Q38101103-0278C754-01BE-4BCE-A3F5-F1F44F024E3A

Q38101103-043A8A81-A589-4440-8376-13CF936753EB

Q38101103-06EF8505-328C-4BEF-800B-D30167711ADF

Q38101103-08103FC1-395C-44E3-9227-0533D5CBD3FF

Q38101103-08A2890B-1818-444A-A748-2A1A738A6593

Q38101103-0A48353E-E0B3-4FB3-A70B-6B0DD4722966

Q38101103-1C85ADF5-5CC3-4386-A710-D1B3132D6D86

Q38101103-1E9CDFDB-FCD9-463A-A934-86B3A9E0F2DB

Q38101103-200D3915-006D-4C66-92EE-8ED1814852DA

P304

Q38101103-08D19237-1D7D-41F0-992D-618504351AAD

P31

Q38101103-E92ECDC5-AC09-4ABE-BF0B-DE3D531B1050

P356

Q38101103-45341207-D969-4877-AC70-76967A02F65D

P433

Q38101103-4545C134-83FD-42E3-A5D5-2F2B6D48E308

P478

Q38101103-DD8C2EAB-D4CA-4467-81D5-004409FB0A55

P50

Q38101103-336A1371-3A0B-4755-B3F8-952F926414E4

Q38101103-F834FCD3-4434-44A5-9865-37EA06EE14EF

P577

Q38101103-B143694F-C07B-4115-BD16-C686DF1EDEAB

P698

Q38101103-3AF86A2F-844D-4272-B94A-932F307CA8D7

P356

P1433

Journal of the European Academy of Dermatology and Venereology

P1476

Imatinib, dasatinib and niloti ...... sis on our clinical experience

@en

P2093

V Grasso

http://www.w3.org/2001/XMLSchema#string

P2860

AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL

Cell signaling by receptor tyrosine kinases

The role of Kit-ligand in melanocyte development and epidermal homeostasis

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

Overriding imatinib resistance with a novel ABL kinase inhibitor

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.

Dasatinib: a review of its use in the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia.

Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).

P304

1471-1480

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/JDV.12172

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

27

http://www.w3.org/2001/XMLSchema#string

P50

Valeria Brazzelli

Giovanni Borroni

P577

2013-04-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23611501

http://www.w3.org/2001/XMLSchema#string